Treatment and prognosis of heart failure with preserved ejection ...
2024年9月18日 · Initial therapy (SGLT2 inhibitor) — In patients with HFpEF (LVEF ≥50 percent) who have New York Heart Association (NYHA) class II to III symptoms, we suggest treatment with a sodium-glucose co-transporter 2 (SGLT2) inhibitor. In patients who cannot take an SGLT2 inhibitor (eg, cost, risk of infection), it is reasonable to initiate therapy ...
2022 AHA/ACC/HFSA Guideline for the Management of Heart …
2022年4月1日 · Guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF) now includes 4 medication classes that include sodium-glucose cotransporter-2 inhibitors (SGLT2i).
Pharmacologic Treatment For HFpEF: Role of Drug Therapies at …
2022年3月8日 · The complex pathophysiology of heart failure with preserved ejection fraction (HFpEF) makes it a diagnostic and therapeutic challenge. Renin-angiotensin aldosterone system inhibitors and sodium-glucose cotransport-2 inhibitors have emerged as promising drug therapies for reducing heart failure hospitalizations in HFpEF.
2023 ACC Expert Consensus on Management of HFpEF: Key Points
2023年4月19日 · Heart failure with preserved ejection fraction (HFpEF) is defined as signs and symptoms of HF with left ventricular EF (LVEF) ≥50%. Diagnosis and management of HFpEF needs multidisciplinary care involving primary care, cardiology, and HF specialists.
Heart Failure With Preserved Ejection Fraction (HFpEF)
2024年3月19日 · The EMPEROR-PRESERVED trial demonstrated significant reductions in cardiovascular mortality, heart failure-related hospitalizations, decline in kidney function, and improved quality of life in patients with HFpEF. The effects of SGLTi therapy are consistent for patients with HFpEF across all age groups, and increasing age has not been ...
Medical Therapies for Heart Failure With Preserved Ejection …
2019年12月2日 · Over the past 16 years, 4 prospective, randomized, placebo-controlled clinical trials using candesartan, perindopril, irbesartan, and spironolactone in patients with heart failure with preserved ejection fraction (HFpEF) failed to demonstrate increased efficacy of RAAS blockade added to guideline-directed medical therapy.
2023 ACC Expert Consensus Decision Pathway on Management of …
Ideally, HFpEF-directed therapy would reduce symptoms of HF, the risk of hospitalization, and mortality. Exercise intolerance is a key symptom of HFpEF; thus, improvement in functional capacity is an important goal.
Heart Failure With Preserved Ejection Fraction: JACC Scientific ...
The past 20 years have witnessed major strides in improved understanding of HFpEF epidemiology, pathophysiology, molecular mechanisms, diagnosis, and treatment. After decades of neutral trials in HFpEF, a proven therapy (SGLT2i) now exists. Nevertheless, major unmet needs and knowledge gaps are still present . As outlined earlier in this paper ...
2024 ACC Expert Consensus Decision Pathway for Treatment of …
2024年3月8日 · Sacubitril/valsartan is 1 of the “4 pillars” of medical care for HFrEF. The 2022 AHA/ACC/HFSA HF guideline 2 recommends sacubitril/valsartan as a Class I, Level of Evidence: A therapy to reduce the risk of HF hospitalization and CV mortality in patients with symptomatic chronic HFrEF (Figures 2 and 3, Table 2).
Drug Therapy for Acute and Chronic Heart Failure with Preserved ...
Various drug therapies are used in the management of acute HFpEF with hypertension, including diuretics, vasodilators, inotropes, anti-hypertensives, and oxygen therapy. A comprehensive summary of these drug classes, pertinent trials, and their effects on blood pressure control and hypertensive complications is provided in Table 1 .